Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics Of Emulsified Avacopan In ANCA-associated Vasculitis With Severe Diffuse Alveolar Hemorrhage
NCT07556484Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2027
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avacopan in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) and Diffuse alveolar hemorrhage (DAH), sponsored by Mayo Clinic. Primary endpoint: Change in Avacopan blood level over time at 72 hours. Planned start Aug 2027; status: recruiting.
02
Drugs
avacopan
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)Diffuse alveolar hemorrhage (DAH)
Beyond the preview
Go deeper on NCT07556484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07556484.